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Si DRUG DISCOVERY IN THE p53 PATHWAY.
D.P. Lane, CRC Laboratories, University of Dundee, DDlI 4HN.
Over 50% of human cancers have mutations in the p53 gene,
yet activation of the p53 response by DNA damage is a key
component regulating the biological consequences of exposure to
therapeutic doses of many chemotherapeutic drugs and ionising
radiation. This implies that the intrinsic resistance of many cancers to
therapy maybe due to loss ofp53 function and conversely that much
of the toxicity to normal cells caused by common anti-cancer
treatments is mediated by p53 activation. Understanding the control
of the p53 pathway thus provides many novel opportunities for drug
discovery to produce novel agents that may act as protectors ofnormal
cells or restore p53 functions to tumour cells. In normal cells exposed
to ionising radiation, p53 levels rise through post translational
stabilisation and p53 becomes active as a transcription factor turning
on the expression of genes such as p21 that induces a cell cycle block
and Bax that promote apoptosis. We have discovered that interaction
with the mdm2 protein is a key regulator of this response. We
isolated, by phage display, peptides that block the p53 binding site on
mdm2. When these are introduced into normal cells (as active site
insertions in the thioredoxin carrier protein) they activate the p53
response and result in the dramatic accumulation of p53 protein.
Studying the mdm2 binding domain ofp53 has allowed us to identify
key phosphorylation sites that are able to reversibly block the binding
of p53 to mdm2. The kinases that modify these sites are also being
identified and thus a complete explanation for the activation ofp53 by
radiation is possible. With this model it will now be possible to re-
examine the in vivo response in which we have observed striking cell
type and tissue type heterogeneity and determine its molecular basis.
It also provides fresh insight into possible mechanisms in individual
variations in the response to radiation and suggests many novel
approaches to cancer treatment.
S3 INTEGRINS, PROTEASES IN ANGIOGENESIS, Peter C.
Brooksl, Steve Sillettil, Tami L. von Schalschal, Martin
Friedlander2 and David A. Cheresh*1. lDepts. of Immunology and
Vascular Biology, 2Dept. of Cell Biology, The Scripps Research Institute,
La Jolla, CA 92037, USA.
Angiogenesis depends on both cell adhesion and proteolytic mechanisms. In
fact, matrix metalloproteinase 2 (MMP-2) and integrin avl3 are
functionally associated on the surface of angiogenic blood vessels. A
fragment of MMP-2 which comprises the C-terminal hemopexin-like
domain, termed PEX, prevents this enzyme binding to avll3 and blocks cell
surface collagenolytic activity. PEX blocks MMP-2 activity on the chick
chorioallantoic membrane where it disrupts angiogenesis and tumor
growth. Importantly, a naturally occurring form of PEX can be detected in
vivo in conjunction with avl3 expression in tumors and during retinal
neovascularization, suggesting that its binding to avP3 on the endothelial
cell surface allows it to serve as a natural inhibitor of protease activity,
thereby regulating the growth of new blood vessels.
InvitedPapers I
MOLECULAR DETECTION OF HUMAN CANCER:
S2 The NextCentury,
David Sidransky, M.D., Department of
Otolaryngology Head & Neck Surgery, Division of Head and Neck
Cancer Research, Johns Hopkins University School of Medicine, 818
Ross Research Building, 720 Rutland Avenue, Baltimore, Maryland
21205-2196, USA; VOX: (410) 502-5153; FAX: (410) 614-1411;
DSIDRANS@WELCHLINK.WELCH.JHU.EDU
Clonal genetic alterations continue show great promise in the
early detection and follow-up of patients with human cancer. In addition
to specific point mutations in proto-oncogenes (e.g. k-ras) or tumor
suppressorgenes (e.g. p53) microsatellite alterations can also be used as
markers to detect the clonal evolution of neoplastic cells. Because these
markers are highly polymorphic, they allow the identification of loss of
heterozygosity resulting from chromosomal deletions or mitotic
recombinations. In addition, microsatellite analysis can also detect the
presence of a new allele indicative of microsatellite instability. In using
these molecular approaches, the ratio of tumor cells to normal cells in a
given clinical sample mustbecarefullyconsidered. These moleculartests
must be developed with a clear understanding ofthe clinical problem and
a limit to thetechnology.
Microsatellite analysis continue to show great promise for the
early detection of bladder cancer, kidney cancer, and head and neck
cancer. Further pilot feasibility studies and multi-institutional trials will
help shed light on the ultimate goal clinical utilityoftheseapproaches.
S4 PROTEASES, PROTEASE INHIBITORS AND CANCER
METASTASIS. M.J. Duffy*, C. Duggan, T. Maguire,
K. McCarthy, E. McDermott and N. O'Higgins, St. Vincent's Hospital, Dublin 4,
Ireland.
Degradation of the interstitial matrix and basement membrane is one
of the key steps in cancer invasion and metastasis. In models systems,
metastatic potential is frequently enhanced by certain proteases and
prevented by certain protease inhibitors. Consistent with their
causative role in cancer progression, we have shown that high levels
of urokinase plasminogen activator (uPA), cathepsin B, cathepsin D
and matrix metalloproteinase 2 (MMP-2) correlate with poor
prognosis in patients with breast cancer.
Of these 4 proteases, uPA was the strongest indicator of patient
outcome and was the only protease prognostic using multivariate
analysis. Furthermore, uPA was the only protease which predicted
outcome in axillary node-negative patients. Contrary to what might be
expected, high levels of 2 protease inhibitors, i.e., PAI-1 and TIMP-1
also correlated with poor outcome. These findings suggest that PAI-1
and TIMP-1 rather than inhibiting breast cancer progression may
enhance the process.
In conclusion, our results with uPA, CB, CD and MMP-2 are
consistent with data from model systems implicating these proteases
in metastasis. On the other hand, our findings with PAI-1 and TIMP-1
are in apparent conflict with that found in experimental metastasis.2 InvitedPapers
S5 REGRESSION OF HUMANTRANSITIONAL CELL
CARCINOMA (TCC) GROWING IN THE BLADDER OF
ATHYMIC NUDE MICE BY BLOCKADE OF EGF-R SIGNAL
TRANSDUCTION. T. Matsumotol, P. Perrottel2, Y. Kim', C.P.N. Dirmey'2, and
*R.Radinsky'. Departments of'CellBiology and2Urology, TheUniversity ofTexas
M. D. Anderson CancerCenter, 1515 Holcombe Boulevard, Houston, Texas 77030.
PUROSE: Epidermal growth factor receptor (EGF-R) is found throughout the
urothelial layer in high-grade transitional cell carcinoma (TCC) and its
overexpression correlates with tumor recurrence and progression. The purpose of
this study was to determine ifEGF-R signaling regulates, in part, human TCC cell
proliferation, invasion, or angiogenesis, and to evaluate whether EGF-Rblockade by
use of (1) dominant negative mutant EGF-Rs, (2) EGF-R specific tyrosine kinase
inhibitors, or (3) neutralizing anti-EGF-R antisera (C225) can have therapeutic
benefits.
METHODS: Human TCC 253J B-V cells were implanted orthotopically into the
bladder wall of athymic nude mice and established tumors (4 weeks) were treated
with intraperitoneal injection of C225 (1 mg, twice/week), oral EGF-R tyrosine
kinase inhibitor (10mg/kg) or PBS. The mice were necropsied at 1, 3 and 5 weeks
after initiation of therapy and tumor growth and metastasis evaluated by tumor
expression oftotal EGF-R, activated EGF-R, p27, CDK2, Rb, MMP9, VEGF, IL-8,
and bFGF using immunohistochemistry (IHC) and in situ mRNA hybridization
(ISH). These data were correlated with microvessel density and apoptosis as
evaluated after CD31 andTUNELIHC, respectively.
RESULTS: In vitro treatment of 253J B-V cells with EGF-R blockade therapies
resulted in inhibition of the EGF-R phosphorylation as measured by Western
blotting, and maximal 50% cytostasis. A decrease was observed in expression ofthe
angiogenic factors VEGF, IL-8 and bFGF and the MMP9 protease by the treated
cells at both mRNA and protein levels in a dose-dependent manner (p<0.005). In
contrast, cell cycle related proteins such as p16, p21 and CDK2 were not
downregulated, although the cyclin-dependent kinase inhibitor, p27, was elevated
after treatment. Systemic therapy of established tumors with EGF-R blockade
therapies resulted in growth inhibition, tumor regression, and abrogation of
metastasis (p<0.0005). Therapy conferred a significant survival advantage to the
treated mice (p=0.0001). The expression ofPCNA, Rb, MMP9, VEGF, IL-8, and
bFGF (protein and mRNA) levels was significantly reduced in treated vs control
tumors (p=0.001); whereasp27 levels were induced tohigh levels. The inhibition of
the angiogenic peptides resulted in the subsequent involution of the tumor
neovascularization as determined by microvessel density (p<0.005) contributing, in
part, to anincreased tumor cell apoptotic index.
CONCLUSION: These experiments indicate that therapeutic strategies targeting
EGF-R signaling have a significant antitumor effect mediated, in part, by the
inhibition of cellular proliferation, invasion, and angiogenesis which leads to
apoptosis and tumorregression.
BACR/ZenecaYoungScientdstAward Lecture
Biochemical Pathways Involved in Activation of p53 During the Cellular
Response to Oxidative Stress
TedHupp, Jeremy Blaydes, Ashley Craig, John Dillon, andDavid Hopwood.
DepartmentofMolecular and CellularPathology, University ofDundee, Dundee, Scotland, DDI 9SY
The tumour suppressor protein p53 is a stress-activated transcription
factor whose activity is required for regulating the cellular response to injury and
whose inactivation in turnours results in loss of damage-inducible cell-cycle
checkpoint pathways. The biochemical mechanism whereby p53 is activated by
damage is not yet defined, but appears to involve multiple steps including:
changes in p53 stability, nuclear transport and ubiquitin-dependent degradation;
mdm2 activity; and site-specific protein kinase function. Data will be presented
which identify key rate-limiting steps that regulate p53 activity in response to
DNA damage in cultured cells, which are, changes inphosphorylation at the CK2,
CDC2, and BXl regulatory sites. Thus, coordinated changes in distinct signaling
cassettes contributes to the damage-dependent activation ofp53 as a transcription
factor.
Placing an emphasis on developing a physiological model to study p53
regulation and dysregulation in tissue systems, biochemical approaches have also
been used to study the effects ofgenotoxic damage and acid-injury on the stress
protein/p53 pathways in normal squamous epithelium. We show that these cells
exhibit an atypical stress-response involving down-regulation ofthe classic stress
protein HSP70, but synthesis ofa novel stress protein named SEP70. The SEP70
protein has been purified from epithelial biopsies for antibody generation and was
found to be functionally related to the glucose-regulated protein ERP70 family.
This stress-protein family has redox activity and presumably plays a role in the
control of oxidative damage in epithelial cells. Current research is centered on
understanding the link between the cellular redox status with p53 activation and
whether dysregulation of the SEP70 pathway plays a role in p53 inactivation
during carcinogenesis insquamous epithelial cells.
S6 TREATMENT OF CANCER WITH MATRIX
METALLOPROTEINASEINHIBITORS,P.Brown,Dept.ofClinical
Research, BritishBiotech Pharmaceuticals, Oxford, OX4 5LY
Matrix metalloproteinases (MMPs) are a family of enzymes
responsible for the breakdown of proteins of connective tissue.
Through this action they play an important role in growth,
development andtissuerepair. Experimental studies also suggestthat
MMPs are utilised in cancer, facilitating both local tumourinvasion
and metastasis. Levels ofcertain MMPs such as stromelysin-3 and
gelatinase areelevatedintumour-associated stromacompared to non-
involved tissue. A series ofsynthetic low molecular weight MMP
inhibitors have been produced. Early inhibitors were based on the
peptide structure of collagen although more recently non-peptide
inhibitors have also beendeveloped. The inhibitors are selective for
the MMP family and are active at low nanomolar concentrations.
Experiments inmodelsofcancerhaveshownthatMMPinhibitors can
significantly reduce the growth rate ofboth primary and secondary
tumours, and can block the process of metastasis. Several MMP
inhibitors have now started clinical trials in patients with advanced
malignancy. Although not the optimum setting for a tumourostatic
agent, earlyresults suggestthis approachmaybe effective in slowing
tumour growth. Trials in the adjuvant setting will provide the most
importanttestofthese inhibitors and should determine theirpotential
tocomplementexistingcytoreductivetreatmentsandprolongsurvival.
S7 TARGETS OF THE ABL TYROSINE KINASES IN
NORMAL AND TRANSFORMED CELLS. Ann Marie
Pendergast*, Dept. of Pharmacology and Cancer Biology,
Duke University Medical Center, Durham, NC 27710
The ABL tyrosine kinases are activated in multiple
human leukemias as a result of structural alterations
of the c-ABL proto-oncogene product. The oncogenic Abl
proteins transform cells by reducing their sensitivity to
apoptotic stimuli, stimulating mitogenic growth, altering
cell adhesion, and as we now show, by inactivation of
negative growth control pathways. We and others have
identified a family of ABL-interactor (Abi) proteins that
bind specifically to both the SH3 and C-terminal proline-
rich sequences of ABL. The Abi proteins are substrates
of the ABL tyrosine kinases and may regulate the
transforming activity of c-ABL. Amino-terminal deletion
of the Abi proteins can activate the oncogenic potential
of the normal c-ABL tyrosine kinase, while overexpression
of larger forms of Abi revert the transformed phenotype
of cells expressing oncogenic ABL proteins. We now show
that oncogenic ABL forms trigger the destruction of Abi
proteins. The destruction of the Abi proteins requires
tyrosine kinase activity and is mediated by the ubiquitin-
proteasome pathway. We show that degradation of the Abi
proteins occurs through a Ras-independent pathway.
Significantly, expression of the Abi proteins is lost in
cell lines and bone marrow cells isolated from patients
with aggressive BCR-ABL-positive leukemias. These
findings suggest that loss of Abi proteins may be a
component in the progression of BCR-ABL-positive leukemias
and identify a novel pathway linking oncogenic ABL
tyrosine kinases to the destruction of target proteins via
the ubiquitin proteasome pathway.Invited Papers 3
S8 EXPERIMENTAL STUDIES OF RADIATION
LEUKAEMOGENESIS
E.G. Wright, Radiation and Genome Stability Unit, Medical Research Council,
Harwell, Oxfordshire OX 1 ORD
Mouse models of specific radiation-induced leukaemias/lymphomas are
valuable for investigating radiogenic damage in the haemopoietic system and the
genetic influences on leukaemia predisposition and pathogenesis. Loss of
heterozygosity (LOH), a characteristic of human radiation-induced leukaemias, is
also characteristic of the mouse models: for example loss of Chromosome 2
sequences in CBA/H mice (acute myeloid leukaemia - AML) and loss of
Chromosome 4 sequences in C57BL/6 mice (thymic lymphoma/leukaemia - TL).
We have induced leukaemias in CBA/H x C57BL6 Fl hybrids and although
microsatellite analyses demonstrate some bias towards Chromosome 2 loss in
AMLs and Chromosome 4 loss in TLs, LOH involving specific chromosomes is is
not leukaemia-specific. Furthermore, there is no specificity for loss of CBA/H
alleles in AMLs or loss of C57BL/6 alleles in TLs. Our analyses have also
indicated the involvement of Chromosome 11 (p53?) in some leukaemias.
Ongoing studies are consistent with LOH being associated with selective
advantage early in radiation leukaemogenesis rather than particular
radiosensitivity associated with a specific chromosome.
In related studies we have demonstrated the induction, by
environmentally relevant doses of ionizing radiation, of chromosomal instability
in primary murine and human haemopoietic stem cells in vitro. The instability is
transmissible in vivo following transplantation of irradiated mouse bone marrow,
its expression has a strong dependence on genotype and aberrant oxy-radical
metabolism is implicated in the mechanism. The phenotype is remarkably similar
to that of Fanconi Anaemia, a genetically determined chromosomal instability
disorder with aberrant superoxide metabolism and a significant predisposition to
AML. Speculatively, therefore, if there are unexpected effects of environmental
exposures to low doses of radiation for certain genetically predisposed
individuals, then induced instability may be a plausible mechanism for such
effects.
S10 ACQUIRED GENETIC ABNORMALITIES IN ACUTE
LEUKAEMIA: PROMISCUITY AND INCEST, E.
Macintyre, Haematology, H6pital Necker, 149 rue de Sevres,
75743 Paris, FRANCE.
Molecular analysis of the genes involved in recurrent karyotypic abnormalities in
acute leukaemia has led to an explosion in our understanding of the mechanisms
inducing these malignancies and to an improved ability to evaluate prognosis and
therefore to employ risk adapted treatment protocols. The majority of these genes
code for transcription factors involved in the regulation of cell division and/or
differentiation, and many bind to DNA as heterdimers or as higher order protein
complexes. Apart from lymphoid malignancies, in which many of the
abnormalities represent errors of Immunoglobulin or T Cell Receptor
rearrangement, the majority of abnormalities lead to production of a (more or less)
tumour specific fusion transcript and chimeric protein, which can be exploited for
disease follow-up and, at least theoretically, for treatment. Some genes are
predominantly associated with a single partner, whereas others, such as MLL on
chromosome 1 1q23, may have up to 30 partner genes/chromosomes. The latter
may not be required for oncogenic transformation but appear to, at least partly,
determine the leukaemic phenotype. Similarly, the different components of the
CBF complex (CBFa/AMLI and CBFP) are involved in different subgroups of
AML (FAB M2 with t(8;21) and M4Eo with inv(16) respectively) but which
demonstrate morphological, immunophenotypic and prognostic similarities.
Disruption of different members of the same protein complex therefore leads to a
single functional oncogenic outcome. The CBFa/AML1 partner gene can however
have a profound effect on the type of leukaemia, since AML1-ETO (t(8;21)) is
associated with AML, TEL-AML1 (t(12;21)) with ALL and AMLl-EVIl (t(3;21))
with myelodysplasia. Oncogenic similarity can also be seen with different members
of transcription factor families. The b-HLH proteins, for example, are frequently
involved in lymphoid malignancies, including c-MYC in Burkitt's lymphoma and
ALL L3, E2A in B lineage ALL and TALI, TAL2 and LYL1 in T-ALL. TALI,
however, is only oncogenic when associated with aberrant expression ofLM01 or
LM02, demonstrating a requirement for oncogenic synergy. It is therefore
becoming increasingly clear that, while the multi-step oncogenic process may be
sequential (such as in follicular lymphoma), it may also remain silent until all
necessary members of the oncogenic complex have been deregulated, with a
subsequent acute presentation. The fact that several ofthese chimeric proteins act as
part of a complex complicates their functional analysis, since the partner proteins
are often not known and may not be present in a chosen cellular model of induced
constitutive expression.
S9 PRENATAL ORIGIN OF FUSION GENES IN PAEDIATRIC
LEUKAEMIA, M. Greaves, Leukaemia Research Fund Centre,
Institute ofCancer Research, London SW3 6JB
Epidemiological evidence has suggested that some paediatric leukaemias may be
initiated in utero and, for pairs of identical twins with concordant leukaemia, this
possibility has been strongly endorsed by molecular studies of clonality (Greaves
MF, 1997, Lancet, 349:344; Ford AM, Ridge SA, Cabrera ME, Mahmoud H, Steel
CM, Chan LC, Greaves MF, 1993, Nature, 363:358; Ford AM, Pombo-de-Oliveira
MS, McCarthy KP, MacLean JM, Carrico KC, Vincent RF, Greaves M, 1997, Blood,
89:281) We have now characterised the TEL-AMLI genomic sequence in a pair of
monozygotic twins diagnosed at ages 3 years 6 months and 4 years 10 months with
acute lymphoblastic leukaemia. The twin leukaemic DNA shared the same unique
(or clonotypic) but non-constitutive TEL-AMLI fusion sequence (Ford AM, Bennett
CA, Price CM, Bruin MCA, van Wering ER, Greaves M, in press, Proc Nati Acad
Sci USA). The most plausible explanation for this finding is a single cell origin of
the TEL-AML fusion in one foetus in utero, probably as a leukaemia initiating
mutation, followed by intraplacental metastasis of clonal progeny to the other twin.
Direct evidence for a pre-natal origin can only be derived by prospective or
retrospective detection of leukaemia-specific molecular abnormalities in foetal or
newborn samples. We have developed a PCR-based method to scrutinise neonatal
blood spots (Guthrie cards) for the presence of numerically infrequent leukaemic
cells at birth in individuals who subsequently developed leukaemia (Gale KB, Ford
AM, Repp R, Borkhardt A, Keller C, Eden OB, Greaves MF, 1997, Proc Natl Acad
Sci USA, 94:13950). We were able to demonstrate that unique or clonotypic MLL-
AF4 genomic fusion sequences are present in neonatal blood spots from individuals
who were diagnosed with acute lymphoblastic leukaemia at ages 5 months to 2 years
and therefore have arisen during foetal haemopoiesis in utero. This result provides
unequivocal evidence for a pre-natal initiation of acute leukaemia in young patients.
The most frequent translocation in older children with common ALL is the t(l2;21)
TEL-AMLI fusion. We have developed a long range inverse PCR method that
enables us to identify genomic fusion sequences and to design primers for analysing
Guthrie cards from these patients.
Si1 Chronic Myeloid Leukaemia: a paradigm
for malignancy. McCann SR, Gardiner N, Duggan
C, O'Riordan JM, Lawler M. Department of Haematology, St James's
Hospital and Trinity College Dublin, Ireland.
Chronic Myeloid Leukaemia (CML) was the first malignancy to be
associated with a non-random consistent chromosomal abnormality
t(9:22) the so-called Philadelphia chromosome. The hybrid novel gene
(BCRIABL) encodes for a protein which influences cell proliferation
and apoptosis. Until recently treatment was palliative in nature.
Allogeneic bone marrow transplantation (BMT) has however been
associated with prolonged disease-free survival in a majority of
patients. Relapse rates using unmanipulated marrow are low and vary
from 5 to 15%. T cell depletion as a method of Graft versus Host
Disease (GvHD) is associated with a high incidence of leukaemia
relapse. We report on 41 consecutive recipients ofunmanipulated BMT
from histocompatible sibling donors. Patients were conditioned with
Busulfan/cyclophosphamide (33) or cyclophosphamide/TBI (8).
Cyclosporine and methotrexate were used as prophylaxis against
GvHD. All patients engrafted successfully. Three patients (7T) have
had a haematological relapse. Thirty three (80%) patients are alive and
free ofdisease from 2 months to 9 years following BMT. GvHD grade
II-IV occurred in 17 patients and contributed to death in 5. Twenty
recipients were investigated serially for haematopoietic chimaerism
using PCR of short tandem repeats. Twelve patients exhibited
complete donor haematopoiesis at all times and none of these patients
showed evidence of minimal residual disease by RT-PCR of
BCR/ABL.All these remain in complete haematological remission. Six
patients who relapsed (5 sibs, 1 TCD, 1 MUD) were treated with
Donor Lymphocyte Infusions (DLI) reflecting a powerful
immunologically mediated Graft versus Leukaemia effect and all are
alive, in haematological remission and are complete donor chimaeras.
Molecular monitoring of patients following BMT may allow early
intervention with limited toxicity. CML may serve as a useful model
for therapeutic intervention of other malignancies which demonstrate a
consistent chromosomal abnormality.4 Invited Papers
Si 2 REGULATION OFTELOMERESANDTELOMERASE
IN CELLULAR AGING, Jerry W. Shay, Dept. of Cell Biology and
Neuroscience, University of Texas Southwestern Medical Center at
Dallas, 5323 Harry Hines Blvd., Dallas, Texas USA 75235-9039
The telomere/telomerase hypothesis of aging and cancer can be
summarized as follows: 1) progressive telomere loss in all somatic cells
is normal and may be an intrinsic timing mechanism that regulates
cellular senescence; 2) cellular senescence occurs when telomeres are
short; 3) mutation(s) occur in the telomerase repression pathway which
causes the enzyme to upregulate or reactivate; and4) telomerase activity
in cancer cells correlates with the stabilization of telomere length and
cellular immortalization. Many recent experimental advances now permit
rigorous testing of the telomere/telomerase hypothesis of aging and
cancer. These include the cloning of human telomerase template RNA,
the catalytic telomerase protein subunit, a human telomerase associated
protein, as well as the identification of human telomere binding proteins,
and the development oftelomerase activity assays. That telomerase RNA
and the catalytic protein are necessary and sufficient for the production
of human telomerase was demonstrated by the in vitro reconstitution of
telomerase using only these two components. In these experiments,
mutagenesis of the conserved reverse transcriptase residues in the
catalytic protein subunit resulted in loss of the reconstituted activity
providing direct confirmation of its role as the key component of
telomerase (Weinrich, SL et al. Nature Gen 1997, 17:498-502).
Transfection experiments of only the catalytic protein component into
normal human cells without detectable telomerase resulted in restoration
of telomerase activity. Normal human cells stably expressing introduced
telomerase demonstrated extension oflifespan, providing direct evidence
that telomere shortening controls cellular aging (Bodnar, AG et al.
Science 1998, 279:349-352).
S14 OXIDATIVE STRESS ANDAPOPTOSIS
T. G. Cotter, Tumour BiolQgy Laboratory, Dept. of Biochemistry,
University College, Cork, Ireland. email t.cotter@ucc.ie
Apoptosis is a genetically regulated process by which cells
die under a variety of physiological and pathological conditions.
The subcellular signal transduction events driving and
propagating this pivotal biological process are a little unclear at
present. Here we report a role for reactive oxygen intermediates
(ROI) in the early stages of signal transduction in a number of
cell types including tumour cells. A rapid production of
intracellular peroxide was seen when HL-60 and other tumour
cells were exposed to a number of cytotoxic agents, indicating
that a change in redox status was occurring in these cells as they
underwent apoptosis. The induction of apoptosis could be
blocked by pretreating cells with two novel anti-oxidants 3 1-
doxyl a cholestane and 2,2,6,6-tetramethyl-piperdinoxyl. Closer
examination of this peroxide production has identified enzymic
production and/or disruption of resident anti-oxidants as
possible sources. However, in contrast to recent reports
mitochondrial depolarisation did not appear to be required for
the production of peroxides in these cells. Similar results were
seen in primary retinal cultures and peripheral blood cells
indicating that ROI are also important for apoptosis in normal
cells.
The work was supported by the Irish Cancer Society, Health Research Board of
Ireland and The Children's Leukemia Research Project.
S13 IDENTIFICATION OF A GENE ON HUMAN
CHROMOSOME 4 THAT INDUCES SENESCENCE IN A SUBSET OF
IMMORTAL CELLS, 0. Pereira-Smith', Huffington Center on Aging, Baylor
College ofMedicine, Houston, TX 77030
Normal human cells in culture exhibit limited division potential. They
undergo varying numbers of population doublings before entering a metabolically
active, terminally non-dividing state termed cellular senescence. Data from cell
fusion studies support a genetic basis for this phenomenon. Senescence has been
found to be dominant in fusions of normal and immortal human cells, suggesting
immortal cells have defects in cell senescence related genes. Fusions of different
immortal cell lines with each other has led to the identification of four
complementation groups (A-D) for indefinite division indicating that four genes or
genepathways lead to senescence. Chromosome4 has been shown to encode a gene
that induces senescence in immortal cell lines assigned to complementation Group
B. We have cloned a gene on chromosome 4, Mortality Eactor 4, MORF 4, which
upon transfection induces senescence in Group B cell lines while having no effect
on cell lines from the other complementation groups. MORF 4 is a member of a
family of genes and the DNA sequences predict motifs that indicate they are novel
transcription factor/DNA binding proteins. Characterization of MORF 4 and related
family members is in progress. The results should advance our knowledge of the
basic mechanisms involved in regulation ofgrowth of normal and immortal human
cells.
S15 THE MECHANISM OF ACTION OF THE PRO-
APOPTOTIC GENE BAK.
Robin Brown, Tom Raven, Mary Plumpton Laura Dash, Tao Pun,
Alison Winder, Catherine Torgler, Maria-Stella deTiani and
Eric Meldrum
Glaxo-Wellcome, Medicines Research Centre, Gunnels Wood Road,
Stevenage SGI 2NY.
The mechanism ofaction ofthe pro-apoptotic gene bak and bax
remains unknown. Recent evidence has suggested that bax interacts
with cell death components ofthe mitochondria. This results in the
release ofcytochrome c and subsequent caspase activation. While this
model may be true for bax located on the mitochondrial membrane it is
hard to reconcile with the fraction ofboth bax, and particularly bak,
that is localised to the endoplasmic reticulum. In some cells e.g. HeLa
cells; bak protein in predominantly located on the endoplasmic
reticulum and co-localises with known bak binding proteins in addition
to ER-specific markers. Similarly, in the yeast S.pombe bak lethality
requires the function ofthe ER-resident protein calnexin. Recently, a
complex that includes bcl-XL, Bap3 1 and pro-caspase 8 has been
demonstrated to be present on the cytoplasmic face ofthe ER
memebarne and in the budding yeast bax lethality can be blocked by
the overexpression of a previously unknown ER protein. How can we
reconcile these two different pathways? Are they distinct and separate
or is there some crosstalk between apoptotic signals that originate in
the ER and the mitochondria?
KEY WORDS: Apoptosis, HL-60, Oxygen, StressInvited Papers 5
S16 Bc1-2 and other inhibitors of apoptosis: mechanisms of
action.
John C. Reed, MD, PhD
The Burnham Institute
Inhibition of programmed cell death and apoptosis represents a
major step in the pathogenesis of most cancers, promoting clonal
expansion of neoplastic cells, evasion of immune responses, and
resistance to chemo- and radiotherapy. The suppression of cell
death pathways can be achieved by alterations in the expression
or function of apoptosis-regulating proteins that act in the
proximal, intermediate, or distal portions of the pathway.
Examples of each of these will be discussed, including
suppression of Fas/CD95-induced death by the Fas-binding
protein FAP-1 (proximal), interference with mitochondria-
dependent steps of cell death by Bcl-2 (intermediate), and direct
suppression of caspases by IAP-family proteins (distal).
Emphasis will be placed on new insights into the
mechanisms of action of Bcl-2 family proteins. In this regard,
some anti- and pro-apoptotic Bcl-2 family proteins (e.g., Bc1-2, Bcl-
XL, Bax) can form ion-channels in membranes. The
characterization of the events that promote or inhibit formation of
these channels, as well as their physiological significance is under
investigation in our laboratory. Bcl-2, Bcl-XL, and some anti-
apoptotic members of this family also have other functions related
to their ability to bind non-homologous proteins, including Apaf-
1, Raf-1, Calcineurin, and BAG-1/Hsc7O. The functional
significance of these protein-protein interactions for apoptosis
regulation will also be discussed.
Finally, recent evidence from our laboratory will be
presented, demonstrating that IAP family proteins block a distal
step in the cell death pathway by directly binding to certain
caspases (caspases-3, -7, and -9) and potently inhibiting them.